The global company Purolite, headquartered in Bala Cynwyd, PA, is investing in a new state-of-the-art facility at its European R & D Center of Excellence in Wales.
The new center will produce agarose resins used by pharmaceutical developers in the manufacture of modern medicines targeting the treatment of cancer, rheumatoid arthritis and age-related diseases.
There are only a few companies that manufacture resins as part of their product portfolio. Purolite is the only company that focuses exclusively on advanced resin technology.
The Purolite investment in Llantrisant, Wales, was secured with Welsh Government support and will create and safeguard 55 jobs and provide a $160 million plus (£120m) boost for Welsh suppliers over the next five years.
The Welsh Government Economy Minister Edwina Hart said: “This is a high value, strategically important investment for the Llantrisant site and for the advanced materials and manufacturing sector in Wales.
“I have visited the Llantrisant site and was pleased to support the case made by the local management team and I am delighted Welsh Government helped secure this important project.
“It will also create significant economic benefits for the wider economy. The supply chain impacts of the investment are considerable as more than £120m will be spent with Welsh suppliers in the first five years of the project.”
The Minister added that it was anticipated that half of the construction costs of the new facility will be also spent with Welsh building contractors.
Don Brodie, Executive Vice President from Purolite said: “For 31 years we’ve had a presence in Wales through manufacturing and Research and Development. This grant will allow us to grow our high value manufacturing presence here in Wales whilst we continue to develop innovative solutions for our customers”.
Purolite Ltd is wholly owned by Bro-Tech Ltd (UK) which is part of the Purolite Corporation in USA
